Fig. 10.

Expression of HIF-1α and HIF-1 target gene mRNAs in primary breast cancers predicts clinical outcome. Kaplan–Meier analyses of overall survival (120 mo) were performed based on clinical and molecular data for 2,785 breast cancer patients, who were stratified by expression levels in the primary tumor of HIF-1α mRNA (A and B) or a 16-gene HIF-1 signature (C–F), which were greater (red) or less (black) than the median. The P value (log-rank test) and hazard ratio (HR) for each comparison are shown. Patients of all breast cancer types (A and C) or only basal-type breast cancer (B and D) were analyzed. Within these two groups, the subgroup of patients who received only chemotherapy (E and F) was also analyzed.